These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 35659494)
1. Pig models for Duchenne muscular dystrophy - from disease mechanisms to validation of new diagnostic and therapeutic concepts. Stirm M; Fonteyne LM; Shashikadze B; Stöckl JB; Kurome M; Keßler B; Zakhartchenko V; Kemter E; Blum H; Arnold GJ; Matiasek K; Wanke R; Wurst W; Nagashima H; Knieling F; Walter MC; Kupatt C; Fröhlich T; Klymiuk N; Blutke A; Wolf E Neuromuscul Disord; 2022 Jul; 32(7):543-556. PubMed ID: 35659494 [TBL] [Abstract][Full Text] [Related]
2. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462 [TBL] [Abstract][Full Text] [Related]
3. Systemic deletion of Stirm M; Shashikadze B; Blutke A; Kemter E; Lange A; Stöckl JB; Jaudas F; Laane L; Kurome M; Keßler B; Zakhartchenko V; Bähr A; Klymiuk N; Nagashima H; Walter MC; Wurst W; Kupatt C; Fröhlich T; Wolf E Proc Natl Acad Sci U S A; 2023 Jul; 120(29):e2301250120. PubMed ID: 37428903 [TBL] [Abstract][Full Text] [Related]
4. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy. Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980 [TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078 [TBL] [Abstract][Full Text] [Related]
6. CRISPR Therapeutics for Duchenne Muscular Dystrophy. Erkut E; Yokota T Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754 [TBL] [Abstract][Full Text] [Related]
7. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
9. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy. Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342 [TBL] [Abstract][Full Text] [Related]
10. Pig models for translational Duchenne muscular dystrophy research. Stirm M; Klymiuk N; Nagashima H; Kupatt C; Wolf E Trends Mol Med; 2024 May; ():. PubMed ID: 38749865 [TBL] [Abstract][Full Text] [Related]
11. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9. Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865 [TBL] [Abstract][Full Text] [Related]
12. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing. Aslesh T; Erkut E; Yokota T Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973 [No Abstract] [Full Text] [Related]
13. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy. Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M Gene; 2023 May; 867():147358. PubMed ID: 36914142 [TBL] [Abstract][Full Text] [Related]
14. CRISPR technologies for the treatment of Duchenne muscular dystrophy. Choi E; Koo T Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy. Wong TWY; Cohn RD Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172 [TBL] [Abstract][Full Text] [Related]
17. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy. Cai A; Kong X Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609 [TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433 [TBL] [Abstract][Full Text] [Related]